JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences today announced the presentation of preclinical data demonstrating the safety and pharmacokinetics of LX214 as a potential once-daily topical treatment for chronic inflammatory diseases of the eye. LX214 is a clear, micellar, topical formulation of voclosporin, a next-generation calcineurin inhibitor licensed by Lux Biosciences from Isotechnika, Inc. (Edmonton, AB, Canada), which Lux Biosciences is developing as a potential treatment for such conditions as dry eye syndrome, blepharitis, and atopic keratoconjunctivitis.
